Introduction
Peripheral arterial occlusion is a significant complication of several haematological and other systemic disorders ( Table 1 ).
In each of these conditions there is a hypercoagulable state, although the pathogenetic mechanisms leading to thrombosis vary. Acute arterial events tend to occur in subjects with additional risk factors or who already have atherosclerotic disease. They are not confined to the peripheral circulation. In contrast to the inherited thrombophilias in the acquired thrombophilic conditions, there is generally a predisposition to both arterial and venous thromboembolism, and in some conditions to microvascular thrombosis.
Antiphospholipid syndrome
Antiphospholipid syndrome (APS) is an acquired thrombophilia of autoimmune type. 1 It is an important condition because:
. it is associated with significant morbidity and mortality from thrombosis . thrombosis tends to recur . antithrombotic therapy is effective . the diagnosis is easily overlooked.
Clinical features
The principal manifestation is thrombosis. Venous thromboembolism and ischaemic stroke predominate but peripheral arterial thrombosis, and visceral and microvascular thrombosis all occur. 1 Observational studies indicate an especially high risk of recurrent thrombosis unless anticoagulant therapy is maintained. In addition to thrombosis there are many other associations reported. Among the more important are thrombocytopenia and livedo reticularis. Cardiac valve lesions also occur. They range from thickened valves to sterile vegetations with the potential to embolize.
One rare but important complication is catastrophic APS. Acute, diffuse, microvascular occlusion results in life-threatening multiorgan failure. Kidneys, myocardium and lungs (with ARDS) are most commonly affected but digital ischaemia also occurs. 2 Diagnostic criteria for APS include thrombosis in the presence of circulating antiphospholipid antibodies. In some cases the clinical manifestation is pregnancy failure rather than, or as well as, systemic thrombosis. The syndrome may occur against a background of other autoimmune disease, most typically systemic lupus erythematosus, or in previously healthy subjects. The terms secondary and primary APS are applied, respectively.
Antiphospholipid antibodies are detected in two types of assay. First, because some antiphospholipid antibodies inhibit the clotting time of plasma, they can be detected in coagulation-based assays: lupus anticoagulant (LA). Secondly, antiphospholipid antibodies are measured in immunoassays, generally employing the anionic phospholipid cardiolipin as antigen: anticardiolipin antibodies (ACA). However, antiphospholipid antibodies are not specific for APS; they arise in response to infections, for example hepatitis C, HIV and syphilis. They are a transient phenomenon in some other infections such as measles.
Internationally agreed criteria have been formulated to achieve greater consistency in diagnosis 3 (Table 2) . However, these are applicable primarily to enrolment in clinical trials and the diagnosis may be strongly suspected in some individuals who do not fulfil all criteria.
The pathogenesis of thrombosis in APS
The paradox of an increased risk of thrombosis in the presence of antibody which causes delay in clot formation in vitro has been the subject of considerable debate. It is recognized now that the LA effect is due to interference in the assembly of clotting factors on a negatively charged phospholipid surface. For example, the conversion of prothrombin to the pivotal coagulation enzyme thrombin requires the juxtaposition of prothrombin with activated factors X and V on an anionic phospholipid template. This complex is referred to as prothrombinase and its formation The antigenic target of antiphospholipid antibodies (APA) is not phospholipid, in fact, but one of several plasma proteins which bind to anionic phospholipid. 4 These include beta2-glycoprotein I and prothrombin itself. When the protein binds to anionic phospholipid the clustering of antigenic sites permits binding of APA with the relevant antigenic specificity. Other phospholipid binding proteins have been implicated also, including the anticoagulant protein C.
The pathogenesis of the hypercoagulable state in APS appears to be multifactorial. The antibodies are capable of promoting coagulation through a variety of routes. These include an antibody-induced concentration of prothrombin on a phospholipid surface resulting in enhanced thrombin generation, suppression of the protein C anticoagulant pathway, platelet activation through an Fcreceptor-dependent mechanism, binding to and activation of vascular endothelium and induction of tissue factor expression by monocytes. 5À7 From all of the above it will be readily apparent that the terms antiphospholipid antibody and lupus anticoagulant are misnomers:
. Anionic phospholipid is required for antibody binding, but the target epitopes reside on phospholipid binding proteins. . Lupus anticoagulant is an in vitro phenomenon. It is associated with a hypercoagulable state in vivo and is found frequently in the plasma of subjects with thrombosis who have no evidence of systemic lupus erythematosus.
Management of APS
Vessel occlusion in APS is due to thrombus, not vasculitis. The first-line treatment is with antithrombotics, therefore, along with attention to reversible risk factors for thrombosis such as smoking and oestrogen use. Observational studies suggest that aspirin may be insufficient to prevent thrombosis in many cases and anticoagulation with warfarin is generally indicated. Furthermore, retrospective reports indicate that standard intensity warfarin therapy (target INR 2.5) may be inadequate in APS. 8 However, recently reported prospective randomized studies cast doubt on this, at least in relation to venous thromboembolism. 9 Therefore, therapy for thrombosis in APS is warfarin aiming for an INR of 2.5 (range 2À3). Higher intensity warfarin and the addition of aspirin both carry an increased risk of bleeding and should be reserved for cases in which thrombosis recurrence occurs on standard therapy. In many cases long-term anticoagulant therapy is required. If unfractionated heparin is used to treat acute thrombosis the effect of LA on the baseline APTT must be borne in mind in relation to dosage monitoring. Low molecular weight heparin may be preferable, as monitoring is not required in most cases, circumventing this problem.
There is some evidence for aspirin and low-dose heparin for prevention of pregnancy failure in APS, although this is disputed. 10, 11 Immunosuppressive therapy is rarely indicated, an exception being catastrophic APS in which corticosteroids and plasma exchange have been employed on pragmatic grounds.
Heparin-induced thrombocytopenia
Heparin is an occasional cause of limb-and life-threatening thrombosis through an immune-mediated drug reaction which results in thrombocytopenia also. Recognition of heparin-induced thrombocytopenia with thrombosis (HITT) is of great importance 12 because it:
. is easily overlooked . is difficult to confirm by laboratory assessment . may lead to death if heparin is not withdrawn.
Pathogenesis of HITT
Heparin administration often causes a small reduction in the blood platelet count in the first 48 hours. This is of no clinical significance and has been termed type 1 heparin-induced thrombocytopenia. A more marked fall in platelet count occurring between 5 and 14 days after induction of heparin treatment is less common but of great significance because of the accompanying thrombosis risk: type 2 heparin-induced thrombocytopenia or HITT.
The thrombocytopenia is due to consumption in platelet aggregates as a result of platelet activation through surface Fc receptors. This is as a result of binding to the receptor of an immune complex. 12 The complex comprises an antibody to heparin in association with a protein, platelet factor 4 (PF4). PF4 is a heparin binding protein which is a constituent of platelet granules.
Clinical features of HITT Arterial, venous or microvascular occlusion is triggered by the formation of platelet aggregates. Typically, there is extension of arterial thrombosis in subjects receiving heparin for the treatment of arterial occlusion and extension of venous thrombosis or pulmonary embolism in those on therapy for venous thrombosis. Peripheral gangrene may result from arterial, microvascular or major venous thrombosis. Disseminated intravascular coagulation develops in some cases. Untreated, the mortality rate is > 50%.
Diagnosis of HITT
A high index of suspicion is essential. It should be appreciated that:
. Heparin delivered in any dose may cause or perpetuate HITT, including heparin given to maintain patency of intravascular cannulae. The complication is substantially less common with use of low molecular weight heparins. . Thrombosis may occur in HITT in the face of a falling platelet count which is still in the normal range. . HITT may present before 5 days after the introduction of heparin in subjects exposed to heparin within the preceding 12 months.
Immunoassays and bioassays are available for the confirmation of type 2 antibodies but they are variable in their sensitivity and specificity. Immunoassays for heparin= platelet factor 4 antibody are sensitive but have low specificity because such antibodies develop in a large minority of heparin-treated subjects, most of whom do not develop HITT. In contrast, bioassays depend upon activation of normal platelets by patient plasma in the presence of heparin. Although specific for HITT, the assays are not completely sensitive nor reproducible.
Management
The platelet count must be monitored in all subjects exposed to heparin for more than 5 days. In view of the difficulties in confirmation of the diagnosis, heparin of all types and doses should generally be discontinued whenever there is a sustained fall in the platelet count for which there is no more likely cause. This can pose difficulties in the context of the critically ill, such as postoperative patients in an ITU setting.
The high risk of thrombosis persists for several days after with-drawal of heparin and an alternative anticoagulant must be administered. Warfarin use in this situation has been associated with paradoxical and life-threatening thrombosis and is contraindicated. This may be due to the rapid reduction in protein C concentration which occurs after warfarin dosing. Therefore, warfarin should be introduced only well after the thrombocytopenia has resolved.
HITT antibodies usually cross-react with all types of heparin, including low molecular weight formulations, which should not be used in HITT, therefore. An exception may be the synthetic pentasaccharide fondaparinux, but experience with its use is limited at present. The treat-ment of choice is the direct thrombin inhibitor hirudin. 12 The anticoagulant is administered by intravenous infusion as lepirudin and can be monitored using the APTT. Argatroban 1 is an alternative approved treatment in North America. Danaparoid, a heparin analogue, has been used in the management of HITT but has the potential for antibody cross-reactivity, and dose monitoring is problematic also.
Myeloproliferative diseases
The myeloproliferative diseases are predominantly clonal disorders of haemopoiesis characterized by the unregulated proliferation of erythroid, myeloid or megakaryocytic cell lines. In polycythaemia rubra vera (PRV) there is predominantly erythroid hyperplasia resulting in an erythrocytosis, but neutrophil leucocytosis and thrombocytosis may also be present. Essential thrombocythaemia (ET), in contrast, is characterized by thrombocytosis without erythrocytosis; neutrophilia is present also in many cases. In myelofibrosis (MF) there is replacement of haemopoietic bone marrow by reticulin, resulting in bone marrow failure and blood pancytopenia. The stimulus to this is growth factors released locally in bone marrow by clonal megakaryocytes. Chronic myeloid leukaemia (CML) is characterized by the bcr-abl gene rearrangement and blood neutrophil leucocytosis with immature myeloid cells and, often, thrombocytosis. Progression to acute leukaemia is an occasional development in all myeloproliferative diseases and is almost inevitable in CML.
Thrombosis occurs in myeloproliferative diseases, being the major feature in ET and PRV. It is less common in MF and only rarely complicates CML. Thrombosis affects both venous and arterial circulations, including lower limb arteries. Also, microvascular occlusion is a typical complication, especially erythromelalgia. Digital gangrene may ensue. Paradoxically, ET may be associated with a haemorrhagic diathesis, usually when there is an extreme degree of thrombocytosis (platelets >1500 Â 10 9 =l).
The pathogenesis of thrombosis in myeloproliferative disease
This is multifactorial. Blood hyperviscosity in polycythaemia is an undoubted major contributory factor. The risk of thrombosis in myeloproliferative polycythaemia exceeds that in secondary polycythaemias such as due to chronic hypoxia. The role of thrombocytosis in thrombosis in PRV is disputed. However, in ET, the degree of thrombocytosis is positively linked to thrombosis risk, although thrombosis may occur in individuals with counts as low as 400À500 Â 10 9 =l. Abnormal increased platelet reactivity may be responsible and enhanced synthesis of the proaggregatory and vasoconstrictor prostanoid thromboxane A 2 has been recorded. 13 However, other prothrombotic abnormalities have also been reported and there is no clear link between in vitro measurements of platelet reactivity and the occurrence of thrombosis. Recent evidence suggests that the thrombocytosis in some cases of ET results from a non-clonal process and it may be that the risk of thrombosis is lower in such cases, as it is in reactive thrombocytosis.
Diagnosis and management
Because of the widespread use of laboratory investigations, PRV and ET are commonly diagnosed in the subclinical stage. In other cases the presentation is with organ ischaemia (including TIA and stroke, and myocardial and intestinal infarction), venous thrombosis (including limb, portal, mesenteric and intracranial venous thrombosis), erythromelalgia, intractable pruritus exacerbated by bathing or splenomegaly. Diagnosis is by exclusion of reactive thrombocytosis and other causes of polycythaemia. Additional investigations, including bone marrow trephine biopsy and isotopic measurement of red cell mass, are informative in some cases. In PRV and ET life expectancy is many years. Treatment should be aimed at minimizing the risk of thrombosis whilst avoiding increasing the risk of leukaemic transformation through excessive exposure to chemotherapy. In PRV, venesection to maintain the haematocrit in the low normal range is the principal strategy. Although busulphan and radioactive phosphorus have been employed to control high cell counts, hydroxyurea is now preferred as it appears to be less leukaemogenic. However, whether there needs to be close control of thrombocytosis in polycythaemia is not completely clear. 14 In contrast, maintenance of a normal platelet count, usually with hydroxyurea therapy, is the mainstay of treatment in ET. In order to avoid lengthy exposure to cytoreductive therapy, age at diagnosis and the presence of additional thrombotic risk factors are taken into consideration in determination of the timing of introduction of therapy with hydroxyurea. Anagrelide and alphainterferon are alternative treatments for control of thrombocytosis.
Whilst erythromelalgia and transient vascular symptoms in essential thrombocythaemia often respond dramatically to aspirin, and the incidence of recurrent thrombosis is also reduced, aspirin has been associated with increased bleeding in some cases. 15 Individual patient characteristics should be considered in deciding on the introduction of aspirin, therefore. In a recent randomized trial, aspirin 100 mg daily appeared to reduce thrombotic events significantly in treated subjects with PRV. 16 However, doubts have been raised regarding the generalizabilty of this observation. 17 Other causes of acquired thrombophilia which may cause or contribute to peripheral arterial occlusion include disseminated intravascular coagulation (DIC), cancer and some medications. In DIC the clinical manifestations may be principally haemorrhagic or vaso-occlusive, often with organ failure from ischaemia. Digital gangrene and purpura fulminans are frequent manifestations of DIC in the severely septic patient in the ITU setting, for example. Diagnosis is usually clear from the clinical background and coagulation screening tests. Whether anticoagulation with heparin is a useful therapy in thrombotic DIC continues to be debated, but recent evidence from clinical trials indicates that infusion of activated protein C improves survival in the severely septic patient. 18 This is probably mediated through the immunomodulatory effects of activated protein C as well as its antithrombotic effects.
Activation of coagulation is a frequent feature of malignancy, especially of the gastrointestinal tract, and may result in DIC or more localized thrombosis in arteries or veins. Limb gangrene is a rare presenting feature. Some tumour cells have direct thromboplastic activity whereas in other cases there is activation of monocytes resulting in tissue factor expression and coagulation activation. Thrombosis triggered by malignancy may prove difficult to control using conventional anticoagulant regimens.
In addition to heparin (above), numerous pharmaceuticals may contribute to the development of arterial thrombosis, especially when used in subjects with atheromatous disease. For example, arterial occlusive events are more common in women using the combined oral contraceptive or oral hormone replacement therapy. Tamoxifen and chemotherapeutic agents also predispose to thrombosis.
